A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (RELATIVITY-106)

January 9, 2026 updated by: Bristol-Myers Squibb

A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
83

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 1

Expanded Access

Expanded Access

A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved by the U.S. Food and Drug Administration (FDA). Also called compassionate use. There are different expanded access types.
No longer available

No longer available

  • Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
  • No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
  • Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
  • Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
 outside the clinical trial. See expanded access record.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
  • Phone Number: 855-907-3286
  • Email: Clinical.Trials@bms.com

Study Contact Backup

  • Name: First line of the email MUST contain NCT # and Site #.

Study Locations

  • Australia
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Local Institution - 0045
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Local Institution - 0022
    • Victoria
      • Heidelberg, Victoria, Australia, 3084
        • Local Institution - 0026
      • Melbourne, Victoria, Australia, 3065
        • Local Institution - 0013
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Local Institution - 0017
  • Canada
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Local Institution - 0025
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Local Institution - 0009
  • China
    • Guangdong
      • Guangzhou, Guangdong, China, 510515
        • Local Institution - 0064
    • Shan3xi
      • Xi'an, Shan3xi, China, 710700
        • Local Institution - 0066
  • France
      • Grenoble, France, 38043
        • Local Institution - 0012
      • Nice, France, 06202
        • Local Institution - 0001
      • Reims, France, 51092
        • Local Institution - 0002
      • Rennes, France, 35042
        • Local Institution - 0008
      • Suresnes, France, 92151
        • Local Institution - 0054
    • Cedex 9
      • Avignon, Cedex 9, France, 84918
        • Local Institution - 0021
  • Germany
      • Frankfurt, Germany, 60590
        • Local Institution - 0035
      • Mainz, Germany, 55131
        • Local Institution - 0057
      • Munich, Germany, 81377
        • Local Institution - 0055
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, Germany, 40225
        • Local Institution - 0051
  • Hong Kong
      • Hong Kong, Hong Kong
        • Local Institution - 0004
      • Shatin, Hong Kong, 999077
        • Local Institution - 0031
  • Italy
      • Milan, Italy, 20122
        • Local Institution - 0036
      • Padua, Italy, 35128
        • Local Institution - 0003
      • Roma, Italy, 00168
        • Local Institution - 0010
  • Japan
    • Chiba
      • Kashiwa-shi, Chiba, Japan, 2778577
        • Local Institution - 0047
    • Ehime
      • Matsuyama, Ehime, Japan, 7900024
        • Local Institution - 0048
    • Ishikawa-ken
      • Kanazawa, Ishikawa-ken, Japan, 9208641
        • Local Institution - 0058
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 2320024
        • Local Institution - 0050
    • Osaka
      • Sayama, Osaka, Japan, 5898511
        • Local Institution - 0041
    • Tokyo
      • Chuo-ku, Tokyo, Japan, 104-0045
        • Local Institution - 0063
  • Poland
      • Gdansk, Poland, 80-219
        • Local Institution - 0023
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland, 85-796
        • Local Institution - 0028
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Poland, 02-034
        • Local Institution - 0016
  • Puerto Rico
      • San Juan, Puerto Rico, 00927
        • Local Institution - 0019
    • PR
      • Rio Piedras, PR, Puerto Rico, 935
        • Local Institution - 0052
  • Singapore
      • Singapore, Singapore, 168583
        • Local Institution - 0029
      • Singapore, Singapore, 217562
        • Local Institution - 0027
      • Singapore, Singapore, 308433
        • Local Institution - 0018
      • Singapore, Singapore, 329563
        • Local Institution - 0044
  • South Korea
      • Seoul, South Korea, 138-736
        • Local Institution - 0056
    • Gyeonggido
      • Seongnam-si, Gyeonggido, South Korea, 13496
        • Local Institution - 0037
  • Spain
      • Madrid, Spain, 28046
        • Local Institution - 0053
      • Pamplona, Spain, 31008
        • Local Institution - 0038
      • Zaragoza, Spain, 50009
        • Local Institution - 0040
    • A Coruña
      • Santiago de Compostela, A Coruña, Spain, 15706
        • Local Institution - 0032
    • Cantabria
      • Santander, Cantabria, Spain, 39008
        • Local Institution - 0007
    • Sede Madrid
      • Madrid, Sede Madrid, Spain, 28027
        • Local Institution - 0067
  • Taiwan
      • Taichung, Taiwan, 40705
        • Local Institution - 0024
      • Taipei, Taiwan, 10048
        • Local Institution - 0046
      • Taipei, Taiwan, 11217
        • Local Institution - 0049
    • Tai Zhong Shi
      • District Taichung City, Tai Zhong Shi, Taiwan, 404
        • Local Institution - 0043
  • United States
    • California
      • Los Angeles, California, United States, 90033
        • Local Institution - 0042
      • Los Angeles, California, United States, 90095
        • Local Institution - 0039
      • San Francisco, California, United States, 94115
        • Local Institution - 0034
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20007
        • Local Institution - 0030
    • Maryland
      • Baltimore, Maryland, United States, 21231
        • Local Institution - 0059
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Local Institution - 0060
      • Boston, Massachusetts, United States, 02215
        • Local Institution - 0065
    • New York
      • New York, New York, United States, 10065
        • Local Institution - 0061
      • The Bronx, New York, United States, 10461
        • Local Institution - 0062
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53226
        • Local Institution - 0033

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Histologically confirmed advanced/metastatic hepatocellular carcinoma (HCC)
  • Naïve to systemic therapy for advanced/metastatic HCC (prior neo-adjuvant or adjuvant immunotherapy is permitted if recurrence occurs ≥ 6 months after treatment completion and the case is discussed with BMS medical team)
  • Child-Pugh score of 5 or 6 (ie, Child-Pugh A)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
  • Prior allogenic stem cell or solid organ transplantation
  • Untreated symptomatic central nervous system (CNS) metastases

  • Clinically significant ascites as defined by:

    i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment

Other protocol-defined inclusion/exclusion criteria apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Arm A: Relatlimab + Nivolumab + Bevacizumab
Drug: Nivolumab
Specified dose on specified days
Other Names:
  • BMS-936558
  • Opdivo
Drug: Bevacizumab
Specified dose on specified days
Other Names:
  • Avastin
Drug: Relatlimab
Specified dose on specified days
Other Names:
  • BMS-986016
Experimental: Arm B: Placebo + Nivolumab + Bevacizumab
Other: Placebo
Specified dose on specified days
Drug: Nivolumab
Specified dose on specified days
Other Names:
  • BMS-936558
  • Opdivo
Drug: Bevacizumab
Specified dose on specified days
Other Names:
  • Avastin

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Incidence of dose-limiting toxicities (DLTs)
Time Frame: Up to 6 weeks
Up to 6 weeks
Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Time Frame: Assessed up to 3 years
Assessed up to 3 years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Number of participants with adverse events (AEs)
Time Frame: Up to 135 days after participant's last dose
Up to 135 days after participant's last dose
ORR by BICR per RECIST v1.1 in all randomized participants that are LAG-3 positive
Time Frame: Assessed up to 3 years
Assessed up to 3 years
Overall Survival (OS) of all randomized participants
Time Frame: Assessed up to 3 years
Assessed up to 3 years
OS of all randomized participants that are LAG-3 positive
Time Frame: Assessed up to 3 years
Assessed up to 3 years
Progression Free Survival (PFS) by BICR per RECIST v1.1 in all randomized participants that are lymphocyte activation gene 3 (LAG-3) positive
Time Frame: Assessed up to 3 years
Assessed up to 3 years
PFS by BICR per RECIST v1.1 in all randomized participants
Time Frame: Assessed up to 3 years
Assessed up to 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bristol-Myers Squibb

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 5, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 5, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 18, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 13, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 13, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 20, 2022

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 9, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CA224-106
  • 2021-003606-53 (EudraCT Number)
  • U1111-1267-1579 (Other Identifier: WHO)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings